On average, people lose 15% of their weight in a year or less* with GLP1 Agonists.
Nevermind the incredible weight loss that often seems IMPOSSIBLE to lose, GLP-1 receptor agonists have shown potential in promoting longevity and anti-aging effects beyond their primary purposes.
Research suggests these medications might have broader benefits beyond managing blood sugar levels and weight. They can positively impact cardiovascular health, reduce inflammation, and potentially slow down the aging process at a cellular level.
With this one peptide, you’re protecting your brain and your body from the effects of being overweight. Imagine your life without those extra 20-30 lbs. That you’re carrying 24/7. Multiply that by decades, and you will understand the wear and tear that excess weight causes to your health.
Verdict: Half Truth
When irresponsibly prescribed to patients, side effects can include extended bouts of nausea, vomiting, and heartburn.
However, the real shame is that these side effects can be managed, dampened, or even altogether mitigated with proper clinical guidance.
All it takes is the right prescription of GLP1, the right dose schedule, useful prebiotics, helpful supplements, and proper scheduling of your weekly injections.
Study of temporary gastrointestinal side effects of semaglutide (link).
Verdict: Half Truth
It is important to note that any significant weight loss will cause loss of muscle mass. This is a natural effect of losing a lot of weight.
However, when done right the opposite is actually true. GLP 1’s help muscle utilize glucose more efficiently, improving muscular structure and fibers (link).
By having a nutrition and exercise plan (Zone 1 & 2 training), we substitute the loss of weight and replace it with lean muscle, a key driving force for long term success with weight management, and most importantly, longevity.
1. Xie B, Chen S, Xu Y, Han W, Hu R, Chen M, Zhang Y, Ding S. The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment. Front Pharmacol. 2021 Jun 14;12:697442. doi: 10.3389/fphar.2021.697442. PMID: 34220521; PMCID: PMC8243369 (Link)
2. Chai W, Zhang X, Barrett EJ, Liu Z. Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin’s metabolic action in the presence of insulin resistance. Diabetes. 2014 Aug;63(8):2788-99. doi: 10.2337/db13-1597. Epub 2014 Mar 21. PMID: 24658303; PMCID: PMC4113068 (Link)
3. Abdalqadir, N.; Adeli, K. GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk. Microorganisms 2022, 10, 2061. https://doi.org/10.3390/microorganisms10102061 (Link)
4. Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2020 Aug 1;105(8):e2695–709. doi: 10.1210/clinem/dgaa285. PMID: 32442310; PMCID: PMC7457958 (Link)
5. Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, Chen Z, Luo S, Zheng X, Weng J, Xu S. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021 May 11;17(8):2050-2068. doi: 10.7150/ijbs.59965. PMID: 34131405; PMCID: PMC8193264 (Link)
6. Chen J, Mei A, Wei Y, Li C, Qian H, Min X, Yang H, Dong L, Rao X, Zhong J. GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol. 2022 Dec 8;13:997578. doi: 10.3389/fimmu.2022.997578. PMID: 36569936; PMCID: PMC9772276 (Link)
7. Kim YK, Kim OY, Song J. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Front Pharmacol. 2020 Aug 14;11:1270. doi: 10.3389/fphar.2020.01270. PMID: 32922295; PMCID: PMC7456867 (Link)
8. Sultana R, Sissoho F, Kaushik VP, Raji MA. The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome. Life (Basel). 2022 Aug 12;12(8):1222. doi: 10.3390/life12081222. PMID: 36013401; PMCID: PMC9410036 (Link)